Investor Relation

FILINGS AND DISCLOSURE

SEC Filings

FORM TYPE	RECEIVED	PERIOD END DATE	HTML	XLS
8-K	15/10/2024	09/10/2024	HTML	XLS
8-K	10/10/2024	04/10/2024	HTML	XLS
8-K	25/09/2024	23/09/2024	HTML	XLS
8-K	18/09/2024	14/09/2024	HTML	XLS
DEF 14A	16/09/2024	04/10/2024	HTML	XLS
8-K	12/09/2024	11/09/2024	HTML	XLS
PRE 14A	06/09/2024	06/09/2024	HTML	XLS
8-K	05/09/2024	04/09/2024	HTML	XLS
8-K	28/08/2024	27/08/2024	HTML	XLS
8-K	26/08/2024	26/08/2024	HTML	XLS

Page 1 of 10

Board Diversity Matrix (as of March 26, 2024)

Country of Principal Executive Offices	Malaysia
Disclosure Prohibited under Home Country Law	No
Foreign Private Issuer	No
Total Number of Directors	5

Part I: Gender Identity	Male	Female	Non-Binary	Gender Undisclosed
Directors	5	0	0	0

Part II: Demographic Background
Did Not Disclose Demographic Background	0
LGBTQ+	0
Underrepresented Individual in Home Country Jurisdiction	1

INSIDER DISCLOSURE

Disclosure & News

Title	Date	Type
Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market	20/07/2023	News

Page 1 of 1

Code of Ethics and Business Conduct

We have adopted a code of ethics and business conduct applicable to our directors, officers and employees. This includes our principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions.

Click the pages below or click here for the details.

For further information on investor relation, please email to ir@bionexuslab.com